

Regimen Reference Order – MULTI – larotrectinib

ARIA: MULTI - [larotrectinib]

To order larotrectinib for pediatric patients in ARIA, refer to Additional Information below

Planned Course: Orally twice daily until disease progression or unacceptable toxicity
(1 cycle = 28 days)

Indication for Use: Neurotrophic Tyrosine Receptor Kinase (NTRK) positive tumors

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – MULTI – larotrectinib

Drug	Dose	CCMB Administration Guideline
larotrectinib	<p><u>Adults:</u> 100 mg</p> <p><u>Pediatrics:</u> 100 mg/m² (maximum dose 100 mg; for volume below 1 mL round to nearest 0.1 mL OR for volume above 1 mL round to nearest 0.5 mL)</p>	<p>Orally twice daily with or without food Swallow whole (Self-administered at home)</p>
<p>larotrectinib (VITRAKVI®) available dosage strengths: 25 mg and 100 mg capsules; and 20 mg/mL oral solution Classification: Cytotoxic, Hazardous</p>		

REQUIRED MONITORING

Cycle 1

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes and total bilirubin as per Physician Orders

Day 15

- Liver enzymes and total bilirubin

Cycle 2 and Onwards

Day 1

- CBC, serum creatinine, urea, liver enzymes, total bilirubin, electrolytes as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Patient should notify clinic if they experience neurologic symptoms (e.g. dizziness, mental status changes or gait disturbances)
- larotrectinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit or grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on larotrectinib

ADDITIONAL INFORMATION

- larotrectinib can cause neurological symptoms and cognitive impairment
- larotrectinib can cause hepatotoxicity
- **Ordering in ARIA for pediatric patients:** Support protocol for suspension is available under **larotrectinib** in the “Pediatrics” folder. Manual calculation and manual entry of the dose is required
- larotrectinib will be dispensed by CCMB Pharmacy